Compare Toronto-Dominion Bank (TD) vs Vir Biotechnology Inc. Common Stock (VIR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Toronto-Dominion Bank vs Vir Biotechnology Inc. Common Stock — how do they compare? Toronto-Dominion Bank trades at $117.5 (market cap $191.91B), while Vir Biotechnology Inc. Common Stock trades at $10.2 (market cap $1.80B). The key difference: Toronto-Dominion Bank is far larger — about 106.6× Vir Biotechnology Inc. Common Stock's market cap, and Toronto-Dominion Bank pays a 2.66% dividend while Vir Biotechnology Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Toronto-Dominion Bank for 85 Days and Vir Biotechnology Inc. Common Stock for 0 Days on average.
| TD | VIR | |
|---|---|---|
Market Cap | $191.91B | $1.80B |
Volume | 1,115,140 | 1,782,836 |
Sector | Financials | Health |
52-Week High | $124.80 | $11.78 |
52-Week Low | $78.72 | $5.12 |
Typical Hold Time | 85 Days | 0 Days |
Enterprise Value | $568.32B | $1.36B |
Dividend Yield | 2.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TD (Toronto-Dominion Bank) trades at $117.63, up 0.98% today, with a bearish technical signal but strong fundamentals including a P/E of 18.01 and net income margin of 24.88%. Recent earnings have consistently beaten estimates, and the company announced a $10 billion share buyback program (Proactive Investors, 2026-09-30). Cash flow trends show volatility, with 2025 net cash flow at $1.08 billion. The stock faces headwinds from a high debt-to-asset ratio of 20.86 in 2025, though analyst consensus is bullish with 52.94% buy ratings.
The outlook for TD is mixed: solid profitability and shareholder returns via buybacks and dividends support upside, but technical weakness and elevated debt pose risks. Investors should weigh strong earnings momentum against macroeconomic sensitivity and regulatory scrutiny from ongoing anti-money laundering remediation. The stock's valuation appears reasonable relative to peers, but market sentiment remains cautious due to cash flow inconsistencies.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →About Vir Biotechnology Inc. Common Stock
Vir Biotechnology, Inc. is a US clinical-stage biopharmaceutical company that develops monoclonal antibody-based medicines to treat and prevent serious infectious diseases.
Read more on VIR →
